The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.

Cancer leaves deep emotional scars long after treatment ends, but for many survivors, honest, unfiltered writing can be a ...

When asked to choose a word other than “survivor” to describe myself, I chose “person” because cancer does not define who I ...

After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.